Market Research Logo

Obsessive-Compulsive Disorder - Pipeline Review, H2 2015

Obsessive-Compulsive Disorder - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Obsessive-Compulsive Disorder - Pipeline Review, H2 2015’, provides an overview of the Obsessive-Compulsive Disorder’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Obsessive-Compulsive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obsessive-Compulsive Disorder and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Obsessive-Compulsive Disorder and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Obsessive-Compulsive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Obsessive-Compulsive Disorder pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Obsessive-Compulsive Disorder
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Obsessive-Compulsive Disorder Overview
Therapeutics Development
Pipeline Products for Obsessive-Compulsive Disorder - Overview
Pipeline Products for Obsessive-Compulsive Disorder - Comparative Analysis
Obsessive-Compulsive Disorder - Therapeutics under Development by Companies
Obsessive-Compulsive Disorder - Therapeutics under Investigation by Universities/Institutes
Obsessive-Compulsive Disorder - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Obsessive-Compulsive Disorder - Products under Development by Companies
Obsessive-Compulsive Disorder - Products under Investigation by Universities/Institutes
Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development
AbbVie Inc.
Addex Therapeutics Ltd
C4X Discovery Limited
F. Hoffmann-La Roche Ltd.
Novartis AG
Omeros Corporation
Rottapharm SpA
Sellas Inc.
Obsessive-Compulsive Disorder - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ADX-71743 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADX-88178 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bitopertin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR-5542 Series - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dipraglurant IR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fluvoxamine maleate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mavoglurant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methoxycoronaridine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
zolpidem tartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Obsessive-Compulsive Disorder - Recent Pipeline Updates
Obsessive-Compulsive Disorder - Dormant Projects
Obsessive-Compulsive Disorder - Discontinued Products
Obsessive-Compulsive Disorder - Product Development Milestones
Featured News & Press Releases
Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction
Aug 02, 2007: Jazz Pharmaceuticals, Inc. Announces Submission of Complete Responses to FDA Approvable Letters for Luvox
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Obsessive-Compulsive Disorder, H2 2015
Number of Products under Development for Obsessive-Compulsive Disorder - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Obsessive-Compulsive Disorder - Pipeline by AbbVie Inc., H2 2015
Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd, H2 2015
Obsessive-Compulsive Disorder - Pipeline by C4X Discovery Limited, H2 2015
Obsessive-Compulsive Disorder - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Obsessive-Compulsive Disorder - Pipeline by Novartis AG, H2 2015
Obsessive-Compulsive Disorder - Pipeline by Omeros Corporation, H2 2015
Obsessive-Compulsive Disorder - Pipeline by Rottapharm SpA, H2 2015
Obsessive-Compulsive Disorder - Pipeline by Sellas Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Obsessive-Compulsive Disorder Therapeutics - Recent Pipeline Updates, H2 2015
Obsessive-Compulsive Disorder - Dormant Projects, H2 2015
Obsessive-Compulsive Disorder - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Obsessive-Compulsive Disorder, H2 2015
Number of Products under Development for Obsessive-Compulsive Disorder - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report